Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 9, 2006, Pages 813-815

  He, Nu ^a   Xie, Hong Guang ^c   Collins, Xavier ^b   Edeki, Timi ^d   Yan, Zhengyin ^e  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b MOREHOUSE COLLEGE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ABBOTT LABORATORIES   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CYP2C19; CYP2D6; Ginkgolides; Ginsenosides; Herb drug interactions; Human liver microsome; Quercetin

Indexed keywords

4' HYDROXYMEPHENYTOIN; BIOLOGICAL MARKER; BUFURALOL; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; FLAVONOID; GINKGOLIDE A; GINKGOLIDE B; GINSENOSIDE; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RC; GINSENOSIDE RD; MEPHENYTOIN; QUERCETIN;

ADDITION REACTION; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG USE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HYDROXYLATION; IC 50; INCUBATION TIME; LIVER METABOLISM; LIVER MICROSOME; QUANTUM YIELD;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FLAVONOIDS; GINKGO BILOBA; GINKGOLIDES; GINSENOSIDES; HUMANS; INHIBITORY CONCENTRATION 50; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES;

EID: 33747066115     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04445.x     Document Type: Article

References (20)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002; 287: 337-44.
2. Draves AH, Walker SE. Analysis of hypericin and pseudohypericin content of commercially available St John's wort preparations. Can. J. Clin. Pharmacol. 2003; 10: 114-18.
3. Xie H-G, Kim RB. St John's wort-associated drug interactions: Short-term inhibition and long-term induction? Clin. Pharmacol. Ther. 2005; 78: 19-24.
4. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-8.
5. Boullata J. Natural health product interactions with medication. Nutr. Clin. Pract. 2005; 20: 33-51.
6. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab. Rev. 2003; 35: 35-98.
7. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 1999; 65: PL209-14.
8. Bedir E, Tatli II, Khan RA et al. Biologically active secondary metabolites from Ginkgo biloba. J. Agric. Food Chem. 2002; 50: 3150-5.
9. Greenblatt DJ, von Moltke LL, Perloff ES et al. Effect of ginkgo on CYP2C9: In vitro and in vivo studies. Clin. Pharmacol. Ther. 2005; 77: P48 (Abstract).
10. He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther. 2004; 11: 206-12.
11. Xie H-G, Frueh FW. Pharmacogenomics steps toward personalized medicine. Personalized Med. 2005; 2: 325-37.
12. 1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur. J. Clin. Pharmacol. 2002; 57: 847-51.
13. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002; 71: 1579-89.
14. Chang TK, Chen J, Benetton SA. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos. 2002; 30: 378-84.
15. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB. Effect of botanical supplementation on cytochrome P450 phenotypes in the elderly. Clin. Pharmacol. Ther. 2005; 77: P16 (Abstract).
16. Morrow JD, Edeki TI, El Mouelhi M et al. American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation. Clin. Pharmacol. Ther. 2005; 77: 113-22.
17. Gurley BJ, Gardner SF, Hubbard MA et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 2002; 72: 276-87.
18. von Moltke LL, Weemhoff JL, Bedir E et al. Inhibition of human cytochrome P450 by components of Ginkgo biloba. J. Pharm. Pharmacol. 2004; 56: 1039-44.
19. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions. Experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-50.
20. MarkowitZ JS, Donovan JL, Devane Lindsay C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol. 2003; 23: 576-81.